通心络胶囊对急性冠脉综合征治疗中的免疫调节作用

Immune Regulation Effects of Tongxinluo Capsule on Acute Coronary Syndrome

目的:探讨通心络胶囊对急性冠脉综合征患者外周血清中炎症细胞因子INF-γ、MMP-9和T淋巴细胞CD4^+CD25^+、CD4^+CD28^-的免疫调节作用。方法:急性冠脉综合征患者共40例,随机分为A、B两组,A组单独给予阿托伐他汀(20 mg/次,1次/d),B组同时给予通心络胶囊(4粒/次,3次/d)和阿托伐他汀(用法同A组),均连续服用4周。使用ELISA检测服药前后外周血清中促炎症细胞因子INF-γ、MMP-9的水平,流式细胞仪检测服药前后T细胞亚组淋巴细胞的比例改变。结果:B组患者服药后外周血中INF-γ、MMP-9表达水平明显降低,CD4^+CD28^-T细胞表达降低,CD4^+CD25^+Tregs表达上调(P<0.05)。结论:通心络胶囊可下调急性冠脉综合征患外周血炎症因子的表达,减少炎症反应,且可以调节CD4^+CD28^-T细胞和CD4^+CD25^+Treg细胞数量,在急性冠脉综合征治疗中具有免疫调节作用。

Objective： To explore the immurne regulation effects of Tongxinluo Capsule on acute coronary syndrome. Methods ： 40 patients were randomly divided into 2 groups.Group A were treated by Atorvastatin （ 20 mg, once a day ）, and Group B were treated by Tongxinluo Capsule （ 4 capsules, three times a day ） and Atorvastatin （ 20 mg, once a day ） .The levels of INF- γ and MMP-9 were tested by ELISA, and T cell subsets lymphocyte （ CD4＋CD25＋, CD4＋CD28- ） were measured by the flow cytometry. Results ： Compared to Group A, the levels of INF- γ and MMP-9 were increased （ P〈0.05 ）, and the ratio of CD4＋CD28- T cells were decreased（ P〈0.05 ）, while CD4＊CD25＋ regulatory T cells were increased（ P〈0.05 ） in Group B. Conclusion ： Tongxinluo Capsule can reduce the expressions of proinflammatory factors and regulate the ratio of CD4＋CD25- T cell and CDd＋CD25＋T cell in ACS patients.